HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LCRF-0004

inhibits RON receptor tyrosine kinase; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - LCRF-0004: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - LCRF-0004: 1

Experts

1.	Baird, Anne-Marie: 1 article (01/2019)
2.	Barr, Martin P: 1 article (01/2019)
3.	Byrne, Annette T: 1 article (01/2019)
4.	Cuffe, Sinead: 1 article (01/2019)
5.	Easty, David: 1 article (01/2019)
6.	Fennell, Dean A: 1 article (01/2019)
7.	Finn, Stephen: 1 article (01/2019)
8.	Goparaju, Chandra M: 1 article (01/2019)
9.	Gray, Steven G: 1 article (01/2019)
10.	Griggs, Kim: 1 article (01/2019)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2019 - "Both LCRF-0004 and BMS-777607 demonstrated significant anti-tumor efficacy in vitro, however BMS-777607 was far superior to LCRF-0004. "

Related Drugs and Biologics

1.	N- (4- (2- amino- 3- chloropyridin- 4- yloxy)- 3- fluorophenyl)- 4- ethoxy- 1- (4- fluorophenyl)- 2- oxo- 1,2- dihydropyridine- 3- carboxamide